BCRX
NASDAQ · Biotechnology
Biocryst Pharmaceuticals Inc
$7.69
+0.06 (+0.79%)
Open$7.81
Previous Close$7.63
Day High$7.83
Day Low$7.38
52W High$11.22
52W Low$6.23
Volume—
Avg Volume6.35M
Market Cap1.90B
P/E Ratio—
EPS$-1.50
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+759.8% upside
Current
$7.69
$7.69
Target
$66.12
$66.12
$46.17
$66.12 avg
$78.89
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 920.39M | 622.60M | 328.14M |
| Net Income | 277.62M | 169.01M | -56,674,354 |
| Profit Margin | 30.2% | 28.7% | -17.3% |
| EBITDA | 341.98M | 219.77M | -75,730,538 |
| Free Cash Flow | — | — | -52,199,092 |
| Rev Growth | +47.8% | +47.8% | +7.1% |
| Debt/Equity | 2.09 | 2.09 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |